Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of Theophylline for Treatment of Pseudohypoparathyroidism
NCT04240821Phase 2Enrolling by invitation
- Start
- May 2020
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of theophylline in pseudohypoparathyroidism (PHP). Primary endpoint: Adverse Events at 24 months. Started May 2020; status: enrolling by invitation.
02
Drugs
theophylline
03
Conditions
pseudohypoparathyroidism (PHP)
Beyond the preview
Go deeper on NCT04240821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04240821.